Latest Regulatory Progress News

Felix Gold is advancing its Treasure Creek Project in Alaska, aiming for the first domestic antimony concentrate production in over 30 years by late 2025 or early 2026, supported by strong government engagement and solid finances.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.

OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.

PolyNovo Limited reports a robust FY25 with nearly 29% sales growth, a significant cash increase to A$33.5 million, and expanding global market presence. The company’s strategic investments and product innovations signal strong momentum ahead.

Icon Energy Limited reported a stable cash position of $431,414 at the end of June 2025, with no exploration activity during the quarter as it awaits final approval of Petroleum Lease PL-1144. The company plans to pursue joint venture partnerships once the lease is granted.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

First Lithium Limited is on the cusp of securing critical mining license renewals in Mali and anticipates releasing its maiden Mineral Resource Estimate this quarter, while managing funding and exploration cost pressures.

Elementos Limited has delivered a robust Definitive Feasibility Study for its Oropesa Tin Project in Spain, secured a $5 million strategic investment from Metals X, and progressed exploration at its Cleveland Tin Project in Tasmania.

Osteopore Limited reports a three-fold increase in craniofacial implant sales within a year of signing an exclusive distribution deal with Zimmer Biomet, signaling strong early traction across key global markets.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

VRX Silica Limited has successfully concluded the environmental appeal process for its Arrowsmith North Silica Sand Project, with the WA Minister for Environment confirming the adequacy of the EPA assessment. The company is now advancing financing discussions and offtake agreements as it awaits formal project approval.